Our Vision
To restore the lives of those with challenging psychiatric and neurological conditions
About Us
We are dedicated to developing a new class of therapeutics for central nervous system (CNS) disorders that transform the treatment of challenging brain-related conditions. Urgency drives our commitment.
Our Mission
To create treatments for debilitating brain health disorders by developing transformative biopharmaceuticals to address unmet medical needs
Our Commitment
As a Public Benefit Corporation, we are committed to creating transformative biopharmaceutical treatments for brain-related conditions. In recognition of the traditional knowledge and cultural significance of the iboga alkaloids, we have established Healing Forward. Giving Back.TM We will support educational initiatives in collaboration with organizations working within Indigenous communities to preserve natural resources and foster sustainable growth.
PBC Charter
Through our Healing Forward. Giving Back.TM initiative, we honor the cultural tradition of ibogaine by supporting Indigenous communities that have long stewarded the plant. We also work to raise awareness of challenging brain-related conditions, reduce stigma, support those most affected and advance responsible clinical research. When we reach profitability, we will contribute 1% of our annual net profits to provide direct financial assistance while continuing to grow partnerships with mission-aligned organizations.
In Memoriam
Nolan R. Williams, M.D.
June 25, 1982 - October 8, 2025
We honor the life and legacy of Nolan R. Williams, M.D., a brilliant neuroscientist, dedicated clinician and trusted advisor whose work inspired our founding.
-
background
As a Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab, Nolan was a global leader in neuromodulation and plant-based medicine research. Triple board-certified in general neurology, general psychiatry, and behavioral neurology and neuropsychiatry, he brought a comprehensive clinical neuroscience background to his work as an active neuropsychiatrist. His expertise extended to developing and implementing novel therapeutics, including devices and new compounds for central nervous system illnesses.
-
research
Nolan was the first investigator to lead a study of ibogaine that evaluated its neurobiological effects, thereby giving us a window into its potential mechanism of action. His groundbreaking Stanford ibogaine study, published in Nature Medicine, found that ibogaine, when administered with magnesium for cardioprotection, led to significant improvements in PTSD, depression, anxiety and functioning among veterans with traumatic brain injury (TBI).
That research was the genesis of Soneira Inc., PBC, whose purpose is rooted in the science he advanced and the compassion he embodied.
-
career
Throughout his career, Nolan received recognition from the National Institute of Mental Health, One Mind Institute, the Brain Behavior Research Foundation and Stanford Medicine’s Top Scientific Advancements of 2024/2025, among several others. Yet, his greatest legacy is the hope and healing he brought to his patients and their families around the world.
-
legacy
Nolan’s scientific courage, kindness and commitment to innovation continue to guide us as we work diligently to heal complex brain-related conditions, honor the origins of the science that inspired us and give back to the communities connected to it.
Healing Forward and Giving Back are not just our purpose. They are Nolan’s legacy.